WO2001030332A3 - Methods of protecting neuronal function - Google Patents

Methods of protecting neuronal function Download PDF

Info

Publication number
WO2001030332A3
WO2001030332A3 PCT/US2000/029067 US0029067W WO0130332A3 WO 2001030332 A3 WO2001030332 A3 WO 2001030332A3 US 0029067 W US0029067 W US 0029067W WO 0130332 A3 WO0130332 A3 WO 0130332A3
Authority
WO
WIPO (PCT)
Prior art keywords
present
methods
neuronal function
katp
protecting neuronal
Prior art date
Application number
PCT/US2000/029067
Other languages
French (fr)
Other versions
WO2001030332A2 (en
Inventor
David Busija
Original Assignee
Univ Wake Forest
David Busija
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Wake Forest, David Busija filed Critical Univ Wake Forest
Priority to AU13388/01A priority Critical patent/AU1338801A/en
Publication of WO2001030332A2 publication Critical patent/WO2001030332A2/en
Publication of WO2001030332A3 publication Critical patent/WO2001030332A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Abstract

The present invention is generally directed to potassium adenosine triphosphate ('KATP') channel opening compositions. The present invention also relates to the use of KATP channel openers in therapeutic applications. The KATP channel opening compositions of the present invention include diazoxide (7-chloro-3-methyl-2H-1,2,4-benzo-thiadiazine 1,1-dioxide) and aprikalim. According to the present invention, diazoxide and aprikalim can be used independently, or in combination. The present also relates to therapeutic methods for protecting neuronal function utilizing KATP channel openers. Methods of the present invention may be advantageous for protecting neuronal function, prior to medical procedures, after stroke-like events or other events associated with reductions in blood flow, and/or for preserving tissues or organs against cellular injury and death during removal, storage, transplantation or reattachment.
PCT/US2000/029067 1999-10-22 2000-10-20 Methods of protecting neuronal function WO2001030332A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU13388/01A AU1338801A (en) 1999-10-22 2000-10-20 Methods of protecting neuronal function

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16097699P 1999-10-22 1999-10-22
US60/160,976 1999-10-22

Publications (2)

Publication Number Publication Date
WO2001030332A2 WO2001030332A2 (en) 2001-05-03
WO2001030332A3 true WO2001030332A3 (en) 2002-05-10

Family

ID=22579273

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/029067 WO2001030332A2 (en) 1999-10-22 2000-10-20 Methods of protecting neuronal function

Country Status (3)

Country Link
US (1) US6313112B1 (en)
AU (1) AU1338801A (en)
WO (1) WO2001030332A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6521617B2 (en) * 2000-10-13 2003-02-18 The Johns Hopkins University Treatment of apoptotic cell death
JP2006519229A (en) 2003-02-13 2006-08-24 アルバート・アインシュタイン・カレッジ・オヴ・メディシン・オヴ・イェシヴァ・ユニヴァーシティ Regulation of food intake and glucose production by modulation of long-chain fatty acyl-CoA levels in the hypothalamus
US8055347B2 (en) * 2005-08-19 2011-11-08 Brainsgate Ltd. Stimulation for treating brain events and other conditions
US9233245B2 (en) 2004-02-20 2016-01-12 Brainsgate Ltd. SPG stimulation
CA2578224A1 (en) * 2004-08-25 2006-03-09 Essentialis, Inc. Pharmaceutical formulations of potassium atp channel openers and uses thereof
US20070026079A1 (en) * 2005-02-14 2007-02-01 Louis Herlands Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels
AU2006335153B2 (en) * 2006-01-05 2012-03-15 Essentialis, Inc. Salts of potassium ATP channel openers and uses thereof
JP2010532383A (en) * 2007-07-02 2010-10-07 エッセンシャリス，インク． Potassium ATP channel opener salts and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5215985A (en) * 1990-07-20 1993-06-01 E. R. Squibb & Sons, Inc. Method for treating ischemic insult to neurons employing an ATP-sensitive potassium channel blocker
US6031089A (en) * 1996-12-30 2000-02-29 Pharmacia & Upjohn Company Sequences of p56, proteins which affect K-ATP channels

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BARI F ET AL: "Interaction between ATP-sensitive K+ channels and nitric oxide on pial arterioles in piglets.", JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, (1996 NOV) 16 (6) 1158-64., XP001027435 *
CHI, XUEDONG ET AL: "The protective effect of K+ channel openers on.beta.-amyloid induced cerebrovascular endothelial dysfunction", NEUROL. RES. (1999), 21(4), 345-351, XP001027428 *
GARLID K D ET AL: "Cardioprotective effect of diazoxide and its interaction with mitochondrial ATP-sensitive K+ channels. Possible mechanism of cardioprotection.", CIRCULATION RESEARCH, (1997 DEC) 81 (6) 1072-82., XP001027436 *
MIRONOV S L ET AL: "Hypoxia activates ATP-dependent potassium channels in inspiratory neurones of neonatal mice.", JOURNAL OF PHYSIOLOGY, (1998 JUN 15) 509 ( PT 3) 755-66., XP001027321 *
PISSAREK M ET AL: "Tolbutamide attenuates diazoxide -induced aggravation of hypoxic cell injury.", BRAIN RESEARCH, (1998 NOV 23) 812 (1-2) 164-71., XP001027451 *
SZEWCZYK A. ET AL: "Mitochondria: A new target for K+ channel openers ?.", TRENDS IN PHARMACOLOGICAL SCIENCES, (1999) 20/2 (157-161)., XP004172563 *
VELTKAMP R ET AL: "Potassium channel activators protect the N-methyl-D-aspartate-induced cerebral vascular dilation after combined hypoxia and ischemia in piglets.", STROKE, (1998 APR) 29 (4) 837-42;DISCUSSION 842-3., XP001027448 *

Also Published As

Publication number Publication date
AU1338801A (en) 2001-05-08
WO2001030332A2 (en) 2001-05-03
US6313112B1 (en) 2001-11-06

Similar Documents

Publication Publication Date Title
AU5516298A (en) Cerebral protection during carotid endarterectomy and downstream vascular protection during other surgeries
WO2002032225A3 (en) Method of cryopreservation of tissues or organs other than a blood vessel by vitrification
BG103806A (en) Controlled release of pharmaceutical preparations in the front eye chamber
CA2194514A1 (en) Skin protector for ultrasonic-assisted liposuction and accessories
WO2005041656A3 (en) Methods, compositions and devices for inducing stasis in tissues and organs
AU7332094A (en) Solutions for tissue preservation and bloodless surgery and methods using same
BG101446A (en) Antineoplastic cocoa extracts, methods for making, using
CA2374722A1 (en) Universal protective catheter sleeve
CA2429049A1 (en) Vein harvesting system and method
WO2001030332A3 (en) Methods of protecting neuronal function
WO2004103210A3 (en) Tunneling device for use with a graft
EP2269449A3 (en) A composition for the protection and preservation of organs, tissues or cells and the use thereof
CA2340320A1 (en) Use of an angiogenic factor for the treatment of microascular angiopathies
WO2002022152A3 (en) Use of deltorphin a and/or dermorphin h for protection against ischemia and reperfusion injury
ATE426402T1 (en) MEDICAL COMPOSITIONS CONTAINING 2-AMINO-2-A2-(4-OCTYLPHENYL)ETHYLUPROPANE-1,3-DI L
WO2004031129A3 (en) Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
CA2332039A1 (en) The use of a vital dye for facilitating surgical procedures for vitreo-retinal surgery
HUS1900041I1 (en) Use of treosulfan for patient conditioning before bone marrow or blood stem cell transplantation
WO2003043639A3 (en) PHARMACEUTICAL COMPOSITION COMPRISING A ClC-2 CHANNEL OPENER
WO2000054757A3 (en) Use of pirenoxine for the protection of corneal tissues in photokeratectomy
CA2369739A1 (en) Compositions and methods for improving integrity of compromised body passageways and cavities
DE60335202D1 (en) Chaperonin-10-immunosuppression
WO2004060147A3 (en) Tissue and organ preservation, protection and resuscitation
WO1999061010A3 (en) Treatment of infertility with cam-increasing compounds alone or in combination with at least one meiosis-stimulating compound
EP1155677A3 (en) Methods and compositions for inhibiting free radical polymerization in skin and hair

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP